Focus areas: vomiting, anti-nausea medications, constipation, Crohn's disease.
Suggested reading: Rang and Dale, Chapter 30 for gastrointestinal tract information.
The vomiting reflex is complex, involving brain, gut, and muscles.
Key areas in the brain:
Chemoreceptor Trigger Zone (CTZ): Located in the medulla; serves as a sensor for toxins, drugs, and metabolic disturbances.
Vomiting Center (VC): Receives signals from the CTZ and integrates various inputs (gastrointestinal tract, vestibular system, emotional responses).
Dopamine D2 receptors: In CTZ; antagonists used to treat nausea.
Serotonin 5-HT3 receptors: Major factor in chemotherapy-induced nausea; antagonists can be effective.
Histamine H1 receptors: Involved in motion sickness; antagonists used to manage nausea in travel sickness.
Substance P (NK-1 receptors): Associated with delayed phase vomiting; antagonists can help block this response.
H1 Receptor Antagonists (e.g., Promethazine, Cinnarizine)
Mechanism: Block histamine receptors in VC and vestibular system.
Uses: Motion sickness, vertigo, morning sickness.
Side effects: Drowsiness, sedation.
Muscarinic Receptor Antagonists (e.g., Hyoscine)
Mechanism: Block M1 receptors, preventing nausea signals.
Commonly used in travel sickness; relaxes stomach muscles.
Side effects: Dry mouth, blurred vision.
5-HT3 Receptor Antagonists (e.g., Granisetron, Ondansetron)
Mechanism: Block receptors in the peripheral vagus nerve and CTZ.
Generally used pre-chemotherapy to prevent nausea.
Important for comfort during cancer treatment.
NK-1 Receptor Antagonists (e.g., Aprepitant, Fosaprepitant)
Mechanism: Block substance P receptor, inhibiting emetic response.
Used for chemotherapy-induced nausea and postoperative nausea.
Side effects: Diarrhea, fatigue, headaches.
Dopamine D2 Receptor Antagonists (e.g., Domperidone, Metoclopramide)
Mechanism: Block D2 receptors, increasing acetylcholine activity.
Effective for postoperative nausea and delayed gastric emptying.
Side effects: Dry mouth, dizziness, blurred vision.
Types of laxatives: Bulk-forming, stimulant, and fecal softeners.
Mechanism: Absorb water, increase stool bulk, stimulating bowel movement.
Must be taken with adequate fluids to prevent worsening constipation.
Mechanism: Accumulate water & electrolytes, irritate bowel nerves for increased motility.
Commonly used for bowel prep before surgeries but can cause cramping and electrolyte imbalances.
Mechanism: Detergent action to soften stool by mixing water and fats.
Commonly used after bowel surgery to prevent strain.
Crohn's disease is a chronic inflammatory bowel disease affecting any GI tract part.
Causes: Environmental factors, immune dysregulation, genetics, altered gut microbiome.
Symptoms: Abdominal pain, diarrhea, mucus or blood in stools.
Treatment focuses on reducing inflammation and managing symptoms:
5-ASA drugs: For mild cases, reduce gut inflammation.
Corticosteroids: For moderate to severe cases but caution for long-term use.
Immunosuppressants: Control overactive immune response.
Biologics: Target specific inflammatory proteins (TNF inhibitors).
Infliximab: Targets TNF alpha, preventing inflammation cascade.
Vedolizumab: Blocks integrin to reduce T lymphocyte migration into inflamed tissues.
Ustekinumab: Targets interleukin-12 and -23 to reduce inflammatory responses.
Summarized concepts:
Control of vomiting and mechanisms behind antiemetic drugs.
Drug types for treating constipation and their actions.
Overview of Crohn's disease management with a focus on biologics.
Study Tips: Focus on understanding mechanisms, utilize visual aids, and practice clinical scenarios to enhance learning and comprehension.